Allopurinol, oxidative stress and intestinal permeability in patients with cirrhosis: An open-label pilot study

Liver International

Volumn 27, Issue 1, 2007, Pages 54-60

  Spahr, Laurent ^a,b   Bresson Hadni, Solange ^a   Amann, Pauline ^a   Kern, Ilse ^a   Golaz, Olivier ^a   Frossard, Jean Louis ^a   Hadengue, Antoine ^a  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b Department of Gastroenterology and Hepatology ^*  (Switzerland)

Author keywords

Allopurinol; Cirrhosis; Clinical trial; Intestinal permeability; Oxidative stress; Portal hypertension

Indexed keywords

ALLOPURINOL; CYTOKINE; ENDOTOXIN; LACTULOSE; MALONALDEHYDE; MANNITOL;

ADULT; AGED; ALCOHOL ABSTINENCE; ALCOHOL LIVER CIRRHOSIS; ARTICLE; ASCITES; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; INFLAMMATORY DISEASE; INTESTINE INJURY; INTESTINE MUCOSA PERMEABILITY; LIVER BIOPSY; LIVER CIRRHOSIS; MALE; OPEN STUDY; OXIDATIVE STRESS; PATIENT COMPLIANCE; PILOT STUDY; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; SHORT COURSE THERAPY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ALLOPURINOL; ENZYME INHIBITORS; FEMALE; HUMANS; HYPERTENSION, PORTAL; INTESTINES; LIVER CIRRHOSIS; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; PERMEABILITY; PILOT PROJECTS;

EID: 33846418814     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2006.01382.x     Document Type: Article

References (42)

1. Bosch J, Garcia-Pagan JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol 2000; 32: 141-56.
2. Guarner C, Soriano G. Bacterial translocation and its consequences in patients with cirrhosis. Eur J Gastroenterol Hepatol 2005; 17: 27-31.
3. Wong F, Bernardi M, Balk R, et al. Sepsis in cirrhosis: Report on the 7th meeting of the International Ascites Club. Gut 2005; 54: 718-25.
4. Aldersley MA, Howdle PD. Intestinal permeability and liver disease. Eur J Gastroenterol Hepatol 1999; 11: 401-3.
5. Campillo B, Pernet P, Bories PN, Richardet JP, Devanlay M, Aussel C. Intestinal permeability in liver cirrhosis: Relationship with severe septic complications. Eur J Gastroenterol Hepatol 1999; 11: 755-9.
6. Ersoz G, Aydin A, Erdem S, Yuksel D, Akarca U, Kumanlioglu K. Intestinal permeability in liver cirrhosis. Eur J Gastroenterol Hepatol 1999; 11: 409-12.
7. Fujii T, Seki T, Maruoka M, et al. Lactulose-L-rhamnose intestinal permeability test in patients with liver cirrhosis. Hepatol Res 2001; 19: 158-69.
8. Keshavarzian A, Holmes EW, Patel M, Iber F, Fields JZ, Pethkar S. Leaky gut in alcoholic cirrhosis: A possible mechanism for alcohol-induced liver damage. Am J Gastroenterol 1999; 94: 200-7.
9. Pascual S, Such J, Esteban A, et al. Intestinal permeability is increased in patients with advanced cirrhosis. Hepatogastroenterology 2003; 50: 1482-6.
10. Fukui H, Brauner B, Bode JC, Bode C. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: Reevaluation with an improved chromogenic assay. J Hepatol 1991; 12: 162-9.
11. Keshavarzian A, Fields JZ, Vaeth J, Holmes EW. The differing effects of acute and chronic alcohol on gastric and intestinal permeability. Am J Gastroenterol 1994; 89: 2205-11.
12. Bjarnason I, Peters TJ, Wise RJ. The leaky gut of alcoholism: Possible route of entry for toxic compounds. Lancet 1984; 1: 179-82.
13. Such J, Guardiola JV, de Juan J, et al. Ultrastructural characteristics of distal duodenum mucosa in patients with cirrhosis. Eur J Gastroenterol Hepatol 2002; 14: 371-6.
14. Ramachandran A, Prabhu R, Thomas S, Reddy JB, Pulimood A, Balasubramanian KA. Intestinal mucosal alterations in experimental cirrhosis in the rat: Role of oxygen free radicals. Hepatology 2002; 35: 622-9.
15. Schimpl G, Pesendorfer P, Steinwender G, Feierl G, Ratschek M, Hollwarth ME. Allopurinol and glutamine attenuate bacterial translocation in chronic portal hypertensive and common bile duct ligated growing rats. Gut 1996; 39: 48-53.
16. Ghanta RK, Mullen KD. Placebo controlled treatment trials in hepatic encephalopathy are feasible and ethical. Hepatology 2005; 42: 1206-7.
17. Parlesak A, Schafer C, Schutz T, Bode JC, Bode C. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J Hepatol 2000; 32: 742-7.
18. Bode C, Bode JC. Effect of alcohol consumption on the gut. Best Pract Res Clin Gastroenterol 2003; 17: 575-92.
19. Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002; 106: 221-6.
20. Huet PM, Pomier-Layrargues G. The hepatic venous pressure gradient: "remixed and revisited". Hepatology 2004; 39: 295-8.
21. Albillos A, de la Hera A, Gonzalez M, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003; 37: 208-17.
22. Iovino G, Kubow S, Marliss EB. Effect of alpha-phenyl-N-tert-butylnitrone on diabetes and lipid peroxidation in BB rats. Can J Physiol Pharmacol 1999; 77: 166-74.
23. Fukunaga K, Suzuki T, Takama K. Highly sensitive high-performance liquid chromatography for the measurement of malondialdehyde in biological samples. J Chromatogr 1993; 621: 77-81.
24. Ohsawa T, Ohtsubo M. Hepatitis associated with allopurinol. Drug Intell Clin Pharm 1985; 19: 431-3.
25. Swank LA, Chejfec G, Nemchausky BA. Allopurinol-induced granulomatous hepatitis with cholangitis and a sarcoid-like reaction. Arch Intern Med 1978; 138: 997-8.
26. Templar J, Kon SP, Milligan TP, Newman DJ, Raftery MJ. Increased plasma malondialdehyde levels in glomerular disease as determined by a fully validated HPLC method. Nephrol Dial Transplant 1999; 14: 946-51.
27. Del Rio D, Stewart AJ, Pellegrini N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis 2005; 15: 316-28.
28. Szuster-Ciesielska A, Daniluk J, Kandefer-Szerszen M. Oxidative stress in the blood of patients with alcohol-related liver cirrhosis. Med Sci Monit 2002; 8: CR419-24.
29. Yadav D, Hertan HI, Schweitzer P, Norkus EP, Pitchumoni CS. Serum and liver micronutrient antioxidants and serum oxidative stress in patients with chronic hepatitis C. Am J Gastroenterol 2002; 97: 2634-9.
30. Hernandez-Guerra M, Garcia-Pagan JC, Turnes J, et al. Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension. Hepatology 2006; 43: 485-91.
31. Desco MC, Asensi M, Marquez R, et al. Xanthine oxidase is involved in free radical production in type 1 diabetes: Protection by allopurinol. Diabetes 2002; 51: 1118-24.
32. Schimpl G, Pesendorfer P, Steinwender G, Feierl G, Ratschek M, Hollwarth ME. Allopurinol reduces bacterial translocation, intestinal mucosal lipid peroxidation, and neutrophil-derived myeloperoxidase activity in chronic portal hypertensive and common bile duct-ligated growing rats. Pediatr Res 1996; 40: 422-8.
33. Bjarnason I, MacPherson A, Hollander D. Intestinal permeability: An overview. Gastroenterology 1995; 108: 1566-81.
34. Secondulfo M, Iafusco D, Carratu R, et al. Ultrastructural mucosal alterations and increased intestinal permeability in non-celiac, type I diabetic patients. Dig Liver Dis 2004; 36: 35-45.
35. Rao RK, Seth A, Sheth P. Recent advances in alcoholic liver disease I. Role of intestinal permeability and endotoxemia in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2004; 286: G881-4.
36. Ramachandran A, Balasubramanian KA. Intestinal dysfunction in liver cirrhosis: Its role in spontaneous bacterial peritonitis. J Gastroenterol Hepatol 2001; 16: 607-12.
37. Rasaratnam B, Connelly N, Chin-Dusting J. Nitric oxide and the hyperdynamic circulation in cirrhosis: Is there a role for selective intestinal decontamination? Clin Sci (London) 2004; 107: 425-34.
38. Hashimoto N, Ohyanagi H. Effect of acute portal hypertension on gut mucosa. Hepatogastroenterology 2002; 49: 1567-70.
39. Xu WH, Wu XJ, Li JS. Influence of portal pressure change on intestinal permeability in patients with portal hypertension. Hepatobiliary Pancreat Dis Int 2002; 1: 510-4.
40. Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology 2004; 39: 280-2.
41. Butler R, Morris AD, Belch JJ, Hill A, Struthers AD. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 2000; 35: 746-51.
42. Emmerson BT, Gordon RB, Cross M, Thomson DB. Plasma oxipurinol concentrations during allopurinol therapy. Br J Rheumatol 1987; 26: 445-9.